EUVIMEDEUVIMED entdecken
Kohortenstudie

L26/P-702 Anti-Müllerian hormone (AMH) is not predictive of live birth after single euploid frozen embryo transfer beyond embryo ploidy: a retrospective multicenter cohort study

N. Sönmez

Human Reproduction · 01.07.2026 · 41 (Supplement_1)

DOI: 10.1093/humrep/deag083.1031 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von N. Sönmez.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Study question Does baseline serum AMH independently predict live birth after single frozen euploid embryo transfer (FEET) with hormone replacement therapy (HRT), after adjusting embryonic/ endometrial factors? Summary answer Baseline serum AMH did not independently predict live birth after single euploid HRT-FEET following adjustment for embryonic/endometrial factors in regression and structural equation modeling analyses. What is known already Anti-Müllerian hormone is widely used as a robust marker of ovarian reserve and reliably predicts ovarian response, number of oocytes collected, and the probability of obtaining blastocysts in in-vitro fertilization (IVF) cycles. Beyond its quantitative role, AMH has been linked to embryo aneuploidy rates, miscarriage risk, and reproductive outcomes in observational studies. However, these associations are inconsistent and strongly confounded by female age, variable embryo ploidy burden, and non-standardized endometrial preparation. As most studies evaluated AMH in unselected IVF populations without euploid embryo control, it remains unclear whether AMH reflects embryo competence or merely the likelihood of generating transferable embryos. Study design, size, duration The present retrospective cohort analysis incorporated 985 frozen-thawed embryo transfer cycles involving single euploid blastocysts, performed at three IVF centers between March 2018 and July 2024. Clinical data was obtained from the centers’ digital medical documentation system, which prospectively archives patient demographics, endocrine measurements, embryological assessments, and therapeutic outcome variables for each assisted reproduction cycle. Participants/materials, setting, methods Eligible cycles underwent preimplantation genetic testing for aneuploidy (PGT-A) via trophectoderm biopsy with next-generation sequencing. AMH measured within 6 months was categorized as < 1.0, 1.0–3.5, or > 3.5 ng/mL. Exclusions were uterine malformations or cavity pathology affecting implantation, uncontrolled thyroid disease/diabetes/hyperprolactinemia, suspected/confirmed hydrosalpinx, >1 transfer per patient, and natural/modified natural endometrial preparation. Outcomes were live birth (≥24 weeks) and miscarriage. Logistic regression adjusted for age, body mass index, endometrial thickness, biopsy day, and embryo grade. Main results and the role of chance Among 985 PGT-A–confirmed HRT-FEET cycles, higher AMH was associated with greater ovarian/embryologic yield (oocytes retrieved, MII oocytes, 2PN zygotes, and biopsied embryos; all p < 0.0001), while embryo quality and transfer day distribution were similar across AMH categories (p = 0.380 and p = 0.434). Both clinical pregnancy (62.2% vs 61.6% vs 57.0%, p = 0.469) and live birth rates per transfer (53.2% vs 53.0% vs 46.2%, p = 0.244) were comparable across AMH strata. The miscarriage rates were also similar (9.0% vs 8.6% vs 10.8%, p = 0.463). Although AMH levels were comparable between cycles resulting in live birth and those that did not (2.33±2.44 vs 2.60±2.93 ng/mL, p = 0.119), day-5 transfer was more frequent among live births (73.7% vs 62.1%, p < 0.001). Nevertheless, in multivariable logistic regression analysis, AMH did not emerge as an independent predictor of live birth (OR 1.05, 95% CI 1.00–1.10; p = 0.064), whereas Day 5 versus Day 6 embryo transfer was the strongest predictor of live birth (OR 1.70, 95% CI 1.28–2.27; p < 0.001). Limitations, reasons for caution The retrospective methodological approach and risk of residual confounding represent notable constraints. The findings are applicable to single euploid embryo transfers in hormone replacement therapy–based frozen embryo transfer cycles; however, their generalizability to chromosomally unscreened embryos, fresh embryo transfer cycles, natural or modified frozen embryo transfer protocols remains uncertain. Wider implications of the findings Once embryo ploidy and endometrial preparation are normalized, AMH seems to act largely as a quantitative measure (oocyte/embryo yield) rather than predicting live birth per euploid transfer. Counseling may emphasize that AMH reflects expected yield, not euploid embryo implantation competence. Trial registration number No

Zitieren

APA

Sönmez, N. (2026). L26/P-702 Anti-Müllerian hormone (AMH) is not predictive of live birth after single euploid frozen embryo transfer beyond embryo ploidy: a retrospective multicenter cohort study. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.1031

Vancouver

Sönmez N. L26/P-702 Anti-Müllerian hormone (AMH) is not predictive of live birth after single euploid frozen embryo transfer beyond embryo ploidy: a retrospective multicenter cohort study. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.1031

BibTeX
@article{Snmez2026,
  author = {Sönmez, N.},
  title = {L26/P-702 Anti-Müllerian hormone (AMH) is not predictive of live birth after single euploid frozen embryo transfer beyond embryo ploidy: a retrospective multicenter cohort study},
  journal = {Human Reproduction},
  year = {2026},
  volume = {41},
  number = {Supplement_1},
  doi = {10.1093/humrep/deag083.1031}
}
Kostenlos starten →